Purpose: To determine the efficacy and safety profiles of GST (gefitinib as salavage therapy) in patients with advanced recurrent, residual and/or metastatic squamous cell cancer of the head and neck (HNSCC).
Introduction
Worldwide incidence carcinoma of head and neck region in 2012 were 599,637 which was 4.2% of all cancers.
Deaths due to carcinoma of head and neck were 324,834 which was 4% of all cancers [1] . In India alone, 2.5 lakhs new patients are diagnosed every year, of whom about 70% are in an locally advanced stage [2] . Carcinoma of head and neck is one of the commonest malignancies in India and is responsible for 22.9% of cancer related mortality [3] . 
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Approximately 70-80% of these patients are diagnosed with locally advanced disease [4] . Chemoradiation is most preferrable treatment for LAHNC [5, 6] . Local failure rate is high in the range of 60-70%. These patients carry limited prognosis and are suitable for palliative treatment. Palliative treatment is based on many considerations such as borderline performance status (PS), existing co-morbidities, etc [7] . Combination chemotherapy is more effective than single agent chemotherapy but is sometimes not tolerated by patients because of poor nutritional status and general condition of the patients. In view of above, we enrolled thirty patients in this study and they received gefitinib as salvage therapy (GST) in HNSCC.
Material and Methods
Thirty Patients with histologically or cytologically proven diagnosis of locally R/R/M HNSCC from any of the primary sites were candidates for this study who were pretreated (had surgery and/or radiation therapy with/without concomitant chemotherapy). Patients were enrolled for the study after obtaining informed written consent. All patients received Gefitinib 250 mg daily for 3 weeks. Tumor assessment was done by consistent clinical examination after 3 weeks of starting therapy and commencement of next cycles for 6 cycles.
Results
Partial response (PR) was noted in 10% of patients, median progression free survival (PFS) was 3. 
Discussion and Conclusion
Epidermal growth factor receptor (EGFR) , is a transmembrane glycoprotein whose intracellular domain has tyrosine kinase activity. EGFR is involved in in the regulation of cell cycle progression, inhibition of apoptosis, angiogenesis, tumor cell invasion and metastasis. Gefitinib is an inhibitor of tyrosine kinase that blocks the pathway of signal transduction [8] . EGFR is overexpressed in 85% to 95% HNSCC [8] . Gefitinib in a dose dependent manner has been shown to disrupt cell cycle progression [9] .
Baselga et al studied Gefitinib in 28 patients with HNSCC (Total no. of patients=250). Gefitinib in the range 150-800 mg was was favorably tolerated. The most common toxicities reported were diarrhea (47-55%), asthenia (44%) and acnieform follicular rash (46-64%). Stable disease was achieved in 50% of patients HNSCC [10] . Gefitinib 500 mg/day has shown benefit in survival in relation with i.v methotrexate. Overall Response rates were 2.7%, 7.6% and 3.9%, respectively and median OS was 5.6, 6 and 6.7 months, respectively [14] . In our study gefitinib was favorably accepted and had fewer systemic effects and it can be warranted that GST has a potential role in pretreated HNSCC.
